Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVT-301 Safety and PK in Adults With Asthma
NCT02633007Phase 1Completed
- Sponsor
- Acorda Therapeutics
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of levodopa inhalation powder in Parkinson's disease (PD) (2 arms), sponsored by Acorda Therapeutics. Primary endpoint: Change in pulmonary function up to 24 hours. Started Dec 2015; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02633007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633007.